Newsroom
Sorted by: Latest
-
Octagon Urges XFLT Shareholders to Choose a Better Path Forward and Vote AGAINST the Board's Proposed Sub-Adviser Change
NEW YORK--(BUSINESS WIRE)--Octagon Credit Investors, LLC (“Octagon”), a leading credit-focused asset manager, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) and has issued an open letter to shareholders of XAI Floating Rate & Alternative Income Trust (formerly, XAI Octagon Floating Rate & Alternative Income Trust) (the “Fund” or “XFLT”) in connection with the Fund’s upcoming special meeting of shareholders wh...
-
SUI Group Appoints Veteran Technology and Digital Finance Executive Kristina Campbell to Board of Directors
WAYZATA, Minn.--(BUSINESS WIRE)--Sui Group Holdings Limited (NASDAQ: SUIG) (“SUI Group,” “SUIG” or the “Company”), today announced the appointment of Kristina Campbell as an independent director to the Company's Board of Directors (the “Board”), effective immediately. Ms. Campbell will also serve as Chair of the Board's Audit Committee. Ms. Campbell brings more than two decades of executive leadership experience spanning digital assets, fintech, payments, and high-growth technology companies. A...
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO
MUNICH--(BUSINESS WIRE)--The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO)....
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven bios...
-
LQR House Inc. Announces 1-for-100 Reverse Stock Split
MIAMI BEACH, Fla.--(BUSINESS WIRE)--LQR House Inc. (the “Company” or “LQR House”) (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, today announced that the Company’s Board of Directors (the “Board”) approved a reverse stock split (the “Reverse Stock Split”) of LQR House’s shares of Common Stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-100 (the “Reverse Stock Split Ratio”). The Company filed its Certificate of Amendment to...
-
Wotton Kearney selects Intapp DealCloud with Celeste to power relationship intelligence and AI-driven growth
PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp (NASDAQ: INTA), the leading governed AI platform for professional firms in highly regulated industries, today announces that Wotton Kearney has selected Intapp DealCloud with Celeste. The firm will use the platform to unify relationship intelligence and equip its lawyers and business development and marketing teams with AI-driven insights and agentic capabilities.A platform built for international growthWotton Kearney is Asia Pacific's leading specialis...